ScinoPharm to build $37M Taiwan plant for cancer injectables

Seeing a chance to grab a bigger share of the growing market for injectable cancer drugs,Taiwan's ScinoPharm is prepping plans to construct a $37 million manufacturing plant in Tainan Science Park.

Once built, one portion of the plant will house a cytotoxic area meant for the production of high potency cancer products. A separate, isolated area, will house equipment for prefilled syringes for non-cytotoxic products. The entire facility will include space for R&D, quality control, washing, sterilization, manufacturing, filling, lyophilization, packaging and storage.

"The global demand for oncological injectable production capacity far exceeds the supply," noted ScinoPharm President and CEO Jo Shen in a statement. "Many international generic customers of ours have been eagerly searching for partners who can provide a high quality and stable supply of oncological injectable drug products, not to mention meet GMP requirements. We are excited to be able to fill this critical requirement."

ScinoPharm has posts in Taiwan and mainland China. And while China gets a lot of attention for its large-scale outsourcing and pharma manufacturing opportunities, Taiwan has a lot to offer. Tax incentives and an efficient, streamlined drug-approval process have attracted the likes of Chiltern and Sigma-Aldrich ($SIAL) to the island nation.

Construction of the plant is expected to begin later this year, with an opening slated for sometime in 2014, according to ScinoPharm.

- get the ScinoPharm announcement
- learn more from The China Post

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.